Press Releases Medesis Pharma S.A.

Equities

ALMDP

FR0010844464

Market Closed - Euronext Paris Other stock markets 11:35:11 2024-05-24 am EDT			5-day change	1st Jan Change
0.924 ^EUR	-8.51%		-4.74%	+6.45%

2023	Medesis Pharma S.A. Reports Earnings Results for the Half Year Ended June 30, 2023	CI
2023	MEDESIS : Invest Securities confirms its recommendation	CF

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Medesis Pharma S A : Termination of the agreement between NICE and GREEN S.A. and Medesis Pharma	Mar. 19	PU
Medesis Pharma : Résiliation du contrat avec la société NICE & GREEN S.A.	Mar. 19	PU
MEDESIS PHARMA : Apport en trésorerie	Dec. 20	PU
Medesis Pharma S A : END OF ENROLLEMENT OF THE 68 PATIENTS IN MEDESIS PHARMA PHASE 2 CLINICAL STUDY OF NANOLITHIUM FOR THE TREATMENT OF ALZHEIMER’S DISEASE	23-10-17	PU
MEDESIS PHARMA: FAVORABLE REPORT FROM IDSMB EXPERTS ON THE ONGOING PHASE 2 CLINICAL STUDY ON NANOLITHIUM IN THE TREATMENT OF ALZHEIMER'S DISEASE	23-05-23	PU
Medesis Pharma S A : MET EN PLACE UN FINANCEMENT OBLIGATAIRE D’UN MONTANT NOMINAL MAXIMUM POTENTIEL DE 2 500 000 EUROS	23-03-31	PU
MEDESIS PHARMA : ENREGISTREMENT EN EURASIE DU BREVET DE PROTECTION DU CANDIDAT MEDICAMENT POUR LA DECORPORATION DU CESIUM	22-12-12	PU
Medesis Pharma S A : PRÉSENTE UN POSTER SCIENTIFIQUE À LA CONFÉRENCE CLINICAL TRIALS ON ALZHEIMER'S DISEASE DE SAN FRANCISCO	22-11-28	PU
Medesis Pharma S A : PRESENTS A SCIENTIFIC POSTER AT THE CLINICAL TRIALS ON ALZHEIMER'S DISEASE CONFERENCE IN SAN FRANCISCO	22-11-28	PU
Medesis Pharma S A : ANNONCE LA CRÉATION D’UN CONSEIL SCIENTIFIQUE PERMANENT D’EXPERTS EN MALADIES NEURODEGENERATIVES	22-11-21	PU
Medesis Pharma S A : ANNOUNCES THE CONSTITUTION OF A PERMANENT SCIENTIFIC ADVISORY BOARD OF EXPERTS IN NEURODEGENERATIVE DISEASES	22-11-21	PU
MEDESIS PHARMA : RAPPORT FINANCIER SEMESTRIEL 2022	22-10-25	PU
MEDESIS PHARMA : ACTIVITÉS & RÉSULTATS DU 1ER SEMESTRE 2022	22-10-25	PU
Medesis Pharma S A : RENFORCE SA GOUVERNANCE	22-10-04	PU
Medesis Pharma S A : FURTHER STRENGTHENS ITS GOVERNANCE	22-10-04	PU
MEDESIS PHARMA : TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM FIRST INCLUSION OF PATIENTS IN THE PHASE II CLINICAL STUDY	22-06-13	PU
MEDESIS PHARMA : ACTIVITÉS & RÉSULTATS ANNUELS 2021	22-04-13	PU
Medesis Pharma wishes to accelerate the development of its antinuclear products and provides an update on its strategy	22-04-05	AQ
Medesis Pharma S A : - U.S. PATENT PROTECTION REGISTRATION OF THE FUTURE DRUG ALLOWING THE DECORPORATION OF CESIUM	22-03-24	PU
MEDESIS PHARMA : INCLUSION OF FIRST PATIENTS IN CLINICAL TRIAL IN BRAZIL ON NANOMANGANESE FOR THE TREATMENT OF SEVERE FORMS OF COVID-19	22-02-07	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Medesis Pharma S.A.

Equities

ALMDP

FR0010844464

Press Releases

Filters